Intellia Therapeutics (NASDAQ:NTLA) Price Target Increased to $111.00 by Analysts at JMP Securities

Intellia Therapeutics (NASDAQ:NTLAGet Rating) had its target price upped by JMP Securities from $106.00 to $111.00 in a research note published on Monday, The Fly reports. They currently have a market outperform rating on the stock.

Other research analysts have also issued research reports about the stock. StockNews.com upgraded shares of Intellia Therapeutics to a sell rating in a research note on Friday, August 5th. The Goldman Sachs Group cut their price objective on shares of Intellia Therapeutics from $206.00 to $180.00 and set a buy rating on the stock in a research note on Tuesday, May 24th. Credit Suisse Group increased their price objective on shares of Intellia Therapeutics to $101.00 in a research note on Tuesday, August 9th. Chardan Capital reiterated a buy rating and issued a $146.00 price objective on shares of Intellia Therapeutics in a research note on Friday. Finally, Citigroup assumed coverage on shares of Intellia Therapeutics in a research note on Thursday, September 1st. They issued a sell rating and a $50.00 price objective on the stock. Two research analysts have rated the stock with a sell rating, one has given a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of Moderate Buy and an average price target of $123.82.

Intellia Therapeutics Trading Down 3.4 %

Shares of Intellia Therapeutics stock opened at $63.47 on Monday. Intellia Therapeutics has a 12-month low of $37.08 and a 12-month high of $155.63. The firm has a market capitalization of $4.82 billion, a price-to-earnings ratio of -11.86 and a beta of 2.02. The firm’s 50 day simple moving average is $62.95 and its two-hundred day simple moving average is $57.99.

Intellia Therapeutics (NASDAQ:NTLAGet Rating) last issued its quarterly earnings results on Thursday, August 4th. The company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.31) by ($0.02). Intellia Therapeutics had a negative net margin of 883.17% and a negative return on equity of 40.23%. The company had revenue of $14.00 million for the quarter, compared to analyst estimates of $9.50 million. During the same quarter in the previous year, the company posted ($1.01) EPS. The company’s revenue for the quarter was up 115.4% compared to the same quarter last year. On average, sell-side analysts predict that Intellia Therapeutics will post -5.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Intellia Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Intellia Therapeutics during the first quarter valued at $766,000. Frazier Life Sciences Management L.P. purchased a new position in Intellia Therapeutics during the first quarter valued at $14,802,000. Precision Wealth Strategies LLC lifted its holdings in Intellia Therapeutics by 28.4% during the first quarter. Precision Wealth Strategies LLC now owns 12,174 shares of the company’s stock valued at $885,000 after purchasing an additional 2,694 shares in the last quarter. Elmwood Wealth Management Inc. lifted its holdings in Intellia Therapeutics by 0.4% during the second quarter. Elmwood Wealth Management Inc. now owns 67,899 shares of the company’s stock valued at $3,514,000 after purchasing an additional 300 shares in the last quarter. Finally, Prospera Financial Services Inc purchased a new position in Intellia Therapeutics during the first quarter valued at $32,000. 88.18% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

(Get Rating)

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency.

Featured Stories

The Fly logo

Analyst Recommendations for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.